Research analysts at Jefferies Group reduced their price target on shares of Amarin Co. plc (NASDAQ:AMRN) from $24.00 to $20.00 in a report released on Friday, StockRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. Jefferies Group’s price target points to a potential upside of 276.65% from the company’s current price.
The analysts wrote, “We remain focused on the FDA panel meeting in October for ANCHOR and the launch of ANCHOR in 1H14 as the key catalysts for AMRN shares. The company remains in negotiations for a pharma partnership for ANCHOR, but also discussed the merits of self-commercialization.”
A number of other firms have also recently commented on AMRN. Analysts at JPMorgan Cazenove cut their price target on shares of Amarin Co. plc from $18.00 to $12.00 in a research note to investors on Wednesday, July 24th. They now have an “overweight” rating on the stock. Separately, analysts at Oppenheimer cut their price target on shares of Amarin Co. plc from $8.00 to $7.00 in a research note to investors on Tuesday, July 9th. They now have a “market perform” rating on the stock. Finally, analysts at Aegis reiterated a “positive” rating on shares of Amarin Co. plc in a research note to investors on Friday, June 21st.
Shares of Amarin Co. plc (NASDAQ:AMRN) traded up 2.07% during mid-day trading on Friday, hitting $5.42. Amarin Co. plc has a 52 week low of $5.12 and a 52 week high of $14.97. The stock’s 50-day moving average is currently $5.62. The company’s market cap is $816.7 million.
Amarin Co. plc (NASDAQ:AMRN) last released its earnings data on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.38) by $0.12. The company had revenue of $5.50 million for the quarter. Analysts expect that Amarin Co. plc will post $-1.39 EPS for the current fiscal year.
Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.